For example, a super-carbonate-buffered TME via oral administration inhibits tumor growth when combined with anti-PD-1 immunotherapy in melanoma models, thus improving patient survival when combined with adoptive T cell immunotherapy [109,110]. Here, PDCD1 is linked to neoplasm.